Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Go back to Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 35.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.73 | 52 Week High | $4.38 | |||
| Open | $35.73 | 52 Week Low | $1.88 | |||
| Day High | $35.73 | P/E | N/A | |||
| Day Low | $35.73 | EPS | $-1.12 | |||
| Volume | 91 | |||||
